Genome Editing as Therapy for Muscular Dystrophies

Pini, V., et. al. (2017) Current Stem Cell Reports. 3:137-148. https://www.ncbi.nlm.nih.gov/pubmed/28616376

Muscular Dystrophy is one of the many diseases scientists are evaluating for treatment with CRISPR/Cas systems with many labs reporting new findings.  This review provides a survey of current findings and the impact they may have on Muscular Dystrophy treatments.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply